The DOI matches its Crossref record; 512 of the 512 references it cites were found in a registry or an index.
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
Open accessAbstract
Acetylcholinesterase (AChE) plays an important role in the pathogenesis of neurodegenerative diseases by influencing the inflammatory response, apoptosis, oxidative stress and aggregation of pathological proteins. There is a search for new compounds that can prevent the occurrence of neurodegenerative diseases and slow down their course. The aim of this review is to present the role of AChE in the pathomechanism of neurodegenerative diseases. In addition, this review aims to reveal the benefits of using AChE inhibitors to treat these diseases. The selected new AChE inhibitors were also assessed in terms of their potential use in the described disease entities. Designing and searching for new drugs targeting AChE may in the future allow the discovery of therapies that will be effective in the treatment of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
Items 401–512 of 512
Fitzgerald, P. J., Hale, P. J., Ghimire, A., & Watson, B. O. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.620119 · Cited by 30
Yu, Q., Reale, M., Kamal, M. A., Holloway, H. W., Luo, W., Sambamurti, K., Ray, B., Lahiri, D. K., Rogers, J. T., & Greig, N. H. (2013) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523011312020003 · Cited by 29
Akhtar, R. S., Xie, S. X., Brennan, L., Pontecorvo, M. J., Hurtig, H. I., Trojanowski, J. Q., Weintraub, D. A., & Siderowf, A. D. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12290 · Cited by 29
Hassan, M.-A. M., Gad, A. M., Menze, E. T., Badary, O. A., & El‐Naga, R. N. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114140 · Cited by 29
Freund-Levi, Y., Jedenius, E., Tysen-Bäckström, A. C., Lärksäter, M., Wahlund, L.-O., & Eriksdotter, M. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.05.005 · Cited by 28
Cholinergic Deficit and Response to Donepezil Therapy in Parkinson’s Disease with Dementia
Hiraoka, K., Okamura, N., Funaki, Y., Hayashi, A., Tashiro, M., Hisanaga, K., Fujii, T., Takeda, A., Yanai, K., Iwata, R., et al. (2012) · European Neurology · doi:10.1159/000338774 · Cited by 28
Hu, T., Fu, Q., Liu, X., Zhang, H., & Dong, M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.04.002 · Cited by 28
Effects of sage extract on memory performance in mice and acetylcholinesterase activity
Smach, M. A., Hafsa, J., Charfeddine, B., Dridi, H., & Limem, K. (2015) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2015.03.005 · Cited by 28
Rozzini, L., Chilovi, B. V., Bertoletti, E., Trabucchi, M., & Padovani, A. (2007) · Aging Clinical and Experimental Research · doi:10.1007/bf03324693 · Cited by 28
Wang, J., Zhao, C., Kong, P., Bian, G., Sun, Z., Sun, Y., Guo, L., & Li, B. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.08.014 · Cited by 28
Jean, L., Brimijoin, S., & Vaux, D. J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006230 · Cited by 28
Imaging amyloidopathy in Parkinson disease and parkinsonian dementia syndromes
Frey, K. A., & Petrou, M. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0104-4 · Cited by 27
Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease
Park, J.-E., Lee, S., Im, W., Chu, K., & Kim, M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.10.020 · Cited by 27
Enhanced cholinergic-tone during the stress induce a depressive-like state in mice
Fernandes, S. S., Koth, A. P., Parfitt, G. M., Cordeiro, M. F., Peixoto, C. S., Soubhia, A., Moreira, F. P., Wiener, C. D., Oses, J. P., Kaszubowski, E., et al. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.044 · Cited by 26
Galantamine as an Adjunctive Treatment in Major Depression
Elgamal, S., & MacQueen, G. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172756c · Cited by 25 · cited 1×
“Galantamine had a beneficial effect on patients with higher Hamilton Depression Rating Scale (HDRS) scores [349].”
BackgroundGalantamine treatment of cognitive impairment in bipolar disorder: four cases
Schrauwen, E., & Ghaemi, S. N. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00311.x · Cited by 25
Cucurachi, L., Immovilli, P., Granella, F., Pavesi, G., & Cattaneo, L. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0041-5 · Cited by 24
Is donepezil useful for improving cognitive dysfunction in bipolar disorder?
Kelly, T. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.07.027 · Cited by 24
Treatment of Huntington??s disease with galantamine
Petrikis, P., Andreou, C., Piachas, A., Bozikas, V. P., & Karavatos, A. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200401000-00010 · Cited by 24
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Wattmo, C., Jedenius, E., Blennow, K., & Wallin, Å. K. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt156 · Cited by 24
Galasko, D., Farlow, M. R., Lucey, B. P., Honig, L. S., Elbert, D. L., Bateman, R. J., Momper, J. D., Thomas, R. G., Rissman, R. A., Pa, J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01490-z · Cited by 24
Darreh‐Shori, T., Hosseini, S. M., & Nordberg, A. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130845 · Cited by 23
The Amyloid Precursor Protein Represses Expression of Acetylcholinesterase in Neuronal Cell Lines
Hicks, D. A., Makova, N. Z., Gough, M., Parkin, E. T., Nalivaeva, N. N., & Turner, A. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.461269 · Cited by 23
AChE-rich magnopyramidal neurons have a left–right size asymmetry in Broca's area
García, R. R., Montiel, J. F., Villalón, A., Gatica, M. A., & Aboitiz, F. (2004) · Brain Research · doi:10.1016/j.brainres.2004.08.050 · Cited by 23
Ohnishi, T., Sakiyama, Y., Okuri, Y., Kimura, Y., Sugiyama, N., Saito, T., Takahashi, M., & Kobayashi, T. (2014) · Current Alzheimer Research · doi:10.2174/15672050113106660167 · Cited by 23
Sabbagh, M., Cummings, J., Christensen, D., Doody, R., Farlow, M., Liu, L., Mackell, J., & Fain, R. (2013) · BMC Geriatrics · doi:10.1186/1471-2318-13-56 · Cited by 23
Ben‐Shaul, Y., BenMoyal‐Segal, L., Ben‐Ari, S., Bergman, H., & Soreq, H. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04812.x · Cited by 23
Benedito, M. A. C., & Camarini, R. (2001) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2001000100012 · Cited by 23
Srinivasan, E., & Rajasekaran, R. (2018) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2018.12.003 · Cited by 23
Proteolysis in Alzheimer's disease
Periz, G., & Fortini, M. (2000) · EMBO Reports · doi:10.1093/embo-reports/kvd124 · Cited by 22
Gender differences in cholinergic and dopaminergic deficits in Parkinson disease
Kotagal, V., Albin, R. L., Müller, M. L. T. M., Koeppe, R. A., Frey, K. A., & Bohnen, N. I. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1013-1 · Cited by 22
Investigating the binding interactions of galantamine with β-amyloid peptide
Rao, P. P. N., Mohamed, T., & Osman, W. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.111 · Cited by 22
Was Phenserine a Failure or Were Investigators Mislead by Methods?
Becker, R. E., & Greig, N. H. (2012) · Current Alzheimer Research · doi:10.2174/156720512804142912 · Cited by 22
Chen, Y., Bian, Y., Wang, J.-W., Gong, T.-T., Ying, Y., Ma, L., Shan, W., Xie, X., & Zhan, Z. (2020) · ACS Omega · doi:10.1021/acsomega.0c00057 · Cited by 22
Salas, R., Main, A., Gangitano, D. A., Zimmerman, G., Ben‐Ari, S., Soreq, H., & Biasi, M. D. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048454 · Cited by 21
Effect of Prunus domestica L. (mirabelle) on learning and memory in mice
Setareye, S., Shahidi, ., & Mahmoodi, M. (2013) · Ancient Science of Life · doi:10.4103/0257-7941.122996 · Cited by 21
Cognitive function in early clinical phase huntington disease after rivastigmine treatment.
Šešok, S., Bolle, N., Kobal, J., Bucik, & Db, V. (2014) · PubMed · Cited by 21
Ardanı, A. R., Hosseini, G., Bordbar, M. R. F., Talaeı, A., & Toroghi, H. M. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000624 · Cited by 21
Vahedi‐Mazdabadi, Y., Karimpour‐Razkenari, E., Akbarzadeh, T., Lotfian, H., Toushih, M., Roshanravan, N., Saeedi, M., & Ostadrahimi, A. (2020) · PubMed Central · doi:10.22037/ijpr.2019.15514.13139 · Cited by 21
Gotkine, M., Leah, R., Einstein, O., Oded, A., Argov, Z., & Rosenmann, H. (2013) · BioMed Research International · doi:10.1155/2013/845345 · Cited by 20
Şenol, F. S., Ankli, A., Reich, E., & Orhan, İ. E. (2016) · Food Technology and Biotechnology · doi:10.17113/ftb.54.03.16.4225 · Cited by 20
Tulino, R., Benjamin, A. C., Jolinon, N., Smith, D. L., Chini, E. N., Carnemolla, A., & Bates, G. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150682 · Cited by 20
Tober, C., & Schoop, R. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2549-x · Cited by 20
Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression
Pomara, N., Bruno, D., Plaska, C. R., Pillai, A., Ramos‐Cejudo, J., Osorio, R. S., Imbimbo, B. P., Heslegrave, A., Zetterberg, H., & Blennow, K. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.012 · Cited by 20
Kim, M., Jeon, W. K., Lee, K. W., Park, Y. H., & Han, J. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/102734 · Cited by 19
Rivastigmine Patch Ameliorates Depression in Mild AD
Spalletta, G., Gianni, W., Giubilei, F., Casini, A. R., Sancesario, G., Caltagirone, C., & Cravello, L. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318260ab0a · Cited by 19
Jeon, W. K., Ma, J., Choi, B., Han, S., Jin, Q., Hwang, B. Y., & Han, J. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/450838 · Cited by 19
Narirutin produces antidepressant-like effects in a chronic unpredictable mild stress mouse model
Li, Y., Du, Y., Yang, J., Xiu, Z., Ni, Y., Zhang, J., Gao, Y., Li, B., & Shi, H. (2018) · Neuroreport · doi:10.1097/wnr.0000000000001102 · Cited by 19
Greek Sage Exhibits Neuroprotective Activity against Amyloid Beta‐Induced Toxicity
Ververis, A., Savvidou, G., Ioannou, K., Nicolaou, P., Christodoulou, K., & Plioukas, M. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2975284 · Cited by 19
Jangra, A., Arora, M., & Kisku, A. (2020) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_699_19 · Cited by 18
A New Motif in the N‐Terminal of Acetylcholinesterase Triggers Amyloid‐β Aggregation and Deposition
Hou, L., Xu, J., Zhao, Q., Gao, X., Cui, Y., Xu, J., Wang, H., & Chen, H. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12161 · Cited by 18
Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment
Virta, J. R., Laatu, S., Parkkola, R. K., Oikonen, V., Rinne, J. O., & Ruutiainen, J. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511399613 · Cited by 18
de Aragão, B. C., Rodrigues, H. A., Valadão, P. A. C., de Camargo, W. L., Naves, L. A., Ribeiro, F. M., & Guatimosim, C. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2015.12.013 · Cited by 18
Moretti, R., Caruso, P., & Ben, M. D. (2017) · Parkinson s Disease · doi:10.1155/2017/6219851 · Cited by 18
Design, synthesis and cholinesterase inhibitory activity of α-mangostin derivatives
Chi, X., Hou, B., Yang, L., Zi, C., Lv, Y.-F., Jin-yu, L., Ren, F., Yuan, M., Hu, J., & Zhou, J. (2018) · Natural Product Research · doi:10.1080/14786419.2018.1510925 · Cited by 18
Kamath, S. U., Chaturvedi, A., Yerrapragada, D. B., Kundapura, N., Amin, N., & Devaramane, V. (2019) · Europe PMC (PubMed Central) · Cited by 18
Neural Glyoxalase Pathway Enhancement by Morin Derivatives in an Alzheimer’s Disease Model
Frandsen, J. R., Choi, S., & Narayanasamy, P. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00566 · Cited by 18
Gürbüz, P., Dokumacı, A. H., Gündüz, M. G., Pérez, C., Göğer, F., Paksoy, M. Y., Yerer, M. B., & Demirezer, L. Ö. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.01.007 · Cited by 18
Alzheimer disease: current concepts & future directions.
Musiek, E. S., & Schindler, S. E. (2013) · Missouri medicine · Cited by 17
Dzieciolowska, S., Drapeau, P., & Armstrong, G. A. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177005 · Cited by 17
Pinto, G., Bari, M. D., Martin‐Alvarez, R., Sperduti, S., Serrano‐Acedo, S., Gatta, V., Tata, A. M., & Mengod, G. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14125 · Cited by 17
Grauzdytė, D., Raudoniūtė, J., Kulvinskienė, I., Bagdonas, E., Stasiulaitienė, I., Martuzevičius, D., Bironaitė, D., Aldonytė, R., & Venskutonis, P. R. (2019) · Nutrients · doi:10.3390/nu11020218 · Cited by 17
Galantamine plasma concentration and cognitive response in Alzheimer’s disease
Lin, Y., Chou, M., Wu, S.-J., et al. (2019) · PeerJ · doi:10.7717/peerj.6887 · Cited by 17
Kook, M. G., Choi, S. W., Seo, Y., Kim, D. W., Song, B. K., Son, I., Kim, S., & Kang, K. (2017) · Journal of Veterinary Science · doi:10.4142/jvs.2017.18.4.487 · Cited by 16
McCloskey, M. C., Young, T. J., & Anderson, S. M. (2017) · BIOS · doi:10.1893/bios-d-15-00013.1 · Cited by 16
Ma, Y., Ji, J., Li, G., Yang, S., & Pan, S. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5613 · Cited by 16
Hsueh, S., Lecca, D., Greig, N. H., Wang, J., Selman, W. R., Hoffer, B. J., Miller, J. P., & Chiang, Y. H. (2019) · Cell Transplantation · doi:10.1177/0963689719854693 · Cited by 16
Crevier‐Sorbo, G., Rymar, V. V., Crevier-Sorbo, R., & Sadikot, A. F. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0878-0 · Cited by 16
Ishikawa, K., Motoi, Y., Mizuno, Y., Kubo, S., & Hattori, N. (2014) · Psychogeriatrics · doi:10.1111/psyg.12045 · Cited by 15
Hategan, A., & Bourgeois, J. A. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.09.004 · Cited by 15
(-)-Phenserine Attenuates Soman-Induced Neuropathology
Chen, J., Pan, H., Chen, C., Wu, W., Iskandar, K., He, J., Piermartiri, T., Jacobowitz, D. M., Yu, Q., McDonough, J. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099818 · Cited by 15
Guo, P. F., Wang, R., Lian, T., Ding, D.-Y., Zhang, Y., Zhang, W., Li, D.-N., Li, L., Li, J., Guan, H., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.594324 · Cited by 15
Kavanagh, S., Howe, I., Brashear, H. R., Wang, D., van Baelen, B., Todd, M., & Schwalen, S. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256044 · Cited by 14
Ferris, S. H., Karantzoulis, S., Somogyi, M., & Meng, X. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt229 · Cited by 14
Zheng, W., Xiang, Y., Ungvari, G. S., Chiu, F. K. H., Ng, C. H., Wang, Y., & Xiang, Y. (2016) · PubMed · doi:10.11919/j.issn.1002-0829.216003 · Cited by 14
Tsuno, N., Mori, T., Ishikawa, I., Bando, N., Park, H., Matsumoto, Y., Mori, I., Tanaka, M. H., Hirano, T., & Nakamura, Y. (2019) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13644 · Cited by 14
The use of Huperzia species for the treatment of Alzheimer’s disease
Thu, D. K., Vui, D. T., Huyen, N. T. N., Duyen, D. T. K., & Tùng, B. T. (2019) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2019-0159 · Cited by 14
Pachón-Angona, I., Martin, H., Daniel, S., Moraleda, I., Bonet, A., Wnorowski, A., Maj, M., Jóźwiak, K., Iriepa, I., Refouvelet, B., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207652 · Cited by 14
Discovery of Natural Inhibitors of Cholinesterases from Hydrangea: In Vitro and In Silico Approaches
Hwang, J., Youn, K., Lim, G., Lee, J., Kim, D., & Jun, M. (2021) · Nutrients · doi:10.3390/nu13010254 · Cited by 14
Rodrı́guez-Ithurralde, D., Olivera, S., Vincent, O., & Maruri, A. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00245-1 · Cited by 13
Ehrt, U., Fritze, F., & Aarsland, D. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820fce90 · Cited by 13
Wicklund, S., & Wright, M. T. (2012) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.11070160 · Cited by 12
Bipolar affective disorder, type II, apparently precipitated by donepezil
Collins, C., Copeland, B., & Croucher, M. (2010) · International Psychogeriatrics · doi:10.1017/s1041610210002206 · Cited by 12
Do Acetylcholinesterase Inhibitors Increase Anxiety and Depression in Elderly Adults with Dementia?
Jawaid, A., Pawłowicz, E., & Schulz, P. E. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13567 · Cited by 12
Wan, L., Zhen, Y., He, Z., Zhang, Y., Zhang, L., Li, X., Gao, F., & Zhou, X. (2021) · ACS Omega · doi:10.1021/acsomega.1c01404 · Cited by 12
Zarei, S., Shafiei, M., Firouzi, M., Firoozpour, L., Divsalar, K., Asadipour, A., Akbarzadeh, T., & Foroumadi, A. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06683 · Cited by 12
Multiple cholinesterase inhibitors have antidepressant-like properties in the mouse forced swim test
Fitzgerald, P. J., Hale, P. J., Ghimire, A., & Watson, B. O. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113323 · Cited by 12
Rodrı́guez-Ithurralde, D., Maruri, A., & Rodrı́guez, X. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00204-4 · Cited by 10
Bordbar, M. R. F., & Talaeı, A. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31829a88ed · Cited by 9
A rivastigmine-precipitated manic episode in a patient with Alzheimer-type dementia
Tseng, W.-S., & Tzeng, N. (2012) · International Psychogeriatrics · doi:10.1017/s1041610212000701 · Cited by 9
Li, J., Liu, Y., Wang, L., Gu, Z., Huan, Z., Fu, H., & Liu, Q. (2020) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v19i6.12 · Cited by 9
Farlow, M. R., Doraiswamy, P. M., Meng, X., Cooke, K., & Somogyi, M. (2011) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000328745 · Cited by 8
Chen, J., Lu, Jiang, Zhang, Jin, Aubeeluck, Ni, Zhang, Davis, J. M., Xu, et al. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s40503 · Cited by 8
Acetylcholinesterase inhibitors in treatment-resistant psychotic depression
Smart, C., McAllister-Williams, H., & Cousins, D. A. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317718810 · Cited by 8
Shahpouri, M. M., Barekatain, M., Tavakoli, M., Badihian, S., & Shaygannejad, V. (2020) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_154_19 · Cited by 8
High dose rivastigmine in the symptom management of Lewy body dementia
Nour, J. M., Chouliaras, L., & Hickey, L. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-217240 · Cited by 7
Shahpouri, M. M., Barekatain, M., Tavakoli, M., Mirmosayyeb, O., Safaei, A., & Shaygannejad, V. (2020) · Neurology Research International · doi:10.1155/2020/8874424 · Cited by 7
Adjuvant Galantamine for Cognitive Dysfunction in a Patient with Bipolar Disorder
Dias, V. V., Brissos, S., & Gorman, J. M. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200609000-00010 · Cited by 6
Hypercholinergic activity in LRRK2 Parkinson's disease
Bohnen, N. I., & Albin, R. L. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30073-5 · Cited by 6
Yang, L., Wang, Y., Li, N., Xu, B., Duan, J., Yuan, C., Yuan, Q., Yang, Q., Qing, H., Dai, Z., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01338 · Cited by 6
Lecoutey, C., Legay, R., Davis, A., Santos, J. S. O., Dallemagne, P., & Rochais, C. (2021) · Molecules · doi:10.3390/molecules26092536 · Cited by 6
Intérêt des anticholinestérasiques dans les dépressions du sujet âgé
Amara, G., Saâda, W. B., Nasr, S. B., & Ali, B. B. H. (2009) · L Encéphale · doi:10.1016/j.encep.2009.02.004 · Cited by 5
New Magnetic Resonance Imaging Biomarkers Advance the Characterisation of Parkinson’s Disease
Ziegler, D. A., & Corkin, S. (2013) · European Neurological Review · doi:10.17925/enr.2013.08.02.85 · Cited by 5
Keshavrzi, A., Rezaei, H. H., Haghighi, M., & Jahangard, L. (2019) · Neuropsychobiology · doi:10.1159/000501210 · Cited by 5
Najar-Ahmadi, S., Haghaei, H., Farajnia, S., Yekta, R., Ezzati, A., & Rashidi, M. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.115924 · Cited by 5
Murphy, C. A., Paterson, N. E., Chen, A. C.-Y., Arias, W., He, D., Alosio, W., Oakeshott, S., Farrar, A. M., Menalled, L., Ramboz, S., et al. (2014) · International Journal of Comparative Psychology · doi:10.46867/ijcp.2014.27.03.08 · Cited by 4
Electroencephalographic Effects of Galantamine in Major Depressive Disorder
Elgamal, S. A., MARRIOTT, M. J., & MacQUEEN, G. M. (2009) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0b013e3181a184e5 · Cited by 3
Alagiakrishnan, K. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09l00905gry · Cited by 2
Jahanshahi, M., Elyasi, L., Ghazvini, H., et al. (2018) · National Journal of Physiology Pharmacy and Pharmacology · doi:10.5455/njppp.2018.8.1249105022018 · Cited by 2
Morana, P., Mucci, F., Baroni, S., Vecchia, A. D., Piccinni, A., Morana, B., & Marazziti, D. (2020) · Clinical Case Reports · doi:10.1002/ccr3.2462 · Cited by 2
Clarke, Z. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.62544-9 · Cited by 1
Khan (2000) · doi:10.1002/1531-8249(200008)48:2
Cited by
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Shehata, M. K., Ismail, A. A., & Kamel, M. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417928 · Cited by 55
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
“140 These enzymes are critically involved in inflammation regulation, phagocytosis, autophagy, and pathological protein degradation, making them ideal “pathological microenvironmental triggers” for designing enzyme-responsive delivery systems.”
Metal Nanoparticles in Alzheimer’s Disease
Behera, A., Sa, N., Pradhan, S. P., Swain, S., & Sahu, P. K. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-220112 · Cited by 50
Metadata
- Authors
- Walczak-Nowicka, Ł. J., & Herbet, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-27
- Volume
- 22
- Issue
- 17
- Pages
- 9290
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3197674566
- Cited by
- 335
- References
- 512
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.